Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin

Synapse

Volumn 39, Issue 1, 2001, Pages 32-41

  Rothman, Richard B ^a   Baumann, Michael H ^a   Dersch, Christina M ^a   Romero, Dana V ^a   Rice, Kenner C ^b   Carroll, F Ivy ^c   Partilla, John S ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c RTI INTERNATIONAL   (United States)

Author keywords

3,4 methyl enedioxymethampheta mine; Aminorex; Dopamine; Ephedrine; Methamphetamine; Phentermine

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMINOREX; AMPHETAMINE; CENTRAL STIMULANT AGENT; DOPAMINE; EPHEDRINE; METHAMPHETAMINE; NORADRENALIN; PHENTERMINE; SEROTONIN;

ANIMAL TISSUE; ARTICLE; DRUG MECHANISM; DRUG POTENCY; IN VITRO STUDY; NEUROCHEMISTRY; NEUROTRANSMITTER RELEASE; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; RAT;

EID: 0035218082     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3     Document Type: Article

References (59)

1. 3H]BTCP in rat caudate membranes
2. Dopaminergic agonist properties of ephedrine - Theoretical implications
3. Fixed-interval schedule of cocaine reinforcement: Effect of dose and infusion duration
4. Alterations in serotonergic responsiveness during cocaine withdrawal in rats: Similarities to major depression in humans
5. Subjective responses to d-amphetamine alone and after pimozide pretreatment in normal, healthy volunteers
6. High dose pimozide does not block amphetamine-induced euphoria in normal volunteers
7. Evaluation of phentermine and fenfluramine, alone and in combination, in normal, healthy volunteers
8. Dopamine ligands and the stimulus effects of amphetamine: Animal models versus human laboratory data
9. Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: Evidence that dopamine is taken up in vivo by noradrenergic terminals
10. Factors influencing the reinforcing and subjective effects of ephedrine in humans
11. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction
12. Hormonal responses to d- and d,l-fenfluramine in healthy human subjects
13. Monoamine reuptake inhibitors enhance the discriminative state induced by cocaine in the rat
14. The interaction of cocaine with serotonin dorsal raphe neurons. Single-unit extracellular recording studies
15. Flunarizine attenuates cocaine-induced inhibition of A9 dopaminergic neurons
16. The neuroendocrine and behavioral response to dextroamphetamine in normal individuals
17. Treatment of attention-deficit-hyperactivity disorder
18. Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type
19. Psychopathological, neuroendocrine and autonomic effects of 3,4-methyl-enedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study
20. Biological and behavioral responses to D-amphetamine, alone and in combination with the serotonin3 receptor antagonist ondansetron, in healthy volunteers
21. A comparision of fenfluramine and amphetamine in man
22. Chlorphentermine: Absence of amphetamine-like profile in man
23. Predicting the abuse liability of drugs with animal self-administration procedures: Psycomotor stimulants and hallucinogens
24. Discriminative stimulus effects of d-amphetamine, methylphenidate, and diazepam in humans
25. The therapeutic effect of clonidine in attention deficit disorder with hyperactivity: A comparison with placebo and methylphenidate
26. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder
27. 2+ dependence of the amphetamine, nomifensine, and Lu 1989 19-005 effect on in vivo dopamine transmission
28. 2+ dependence of the amphetamine, nomifensine, and Lu 1989 19-005 effect on in vivo dopamine transmission
29. The pharmacology of cocaine related to its abuse
30. The dopamine hypothesis of the reinforcing properties of cocaine
31. Reductions in cocaine-induced craving following the selective D1 dopamine receptor agonist ABT-431 in human cocaine abusers
32. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man
33. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans
34. Effect of acute, short- and long-term milnacipran administration on rat locus coeruleus noradrenergic and dorsal raphe serotonergic neurons
35. Effects of milnacipran and pindolol on extracellular noradrenaline and serotonin levels in guinea pig hypothalamus
36. Effect of dopamine receptor antagonists on cocaine subjective effects: A naturalistic case study
37. Effects of acute pretreatment with risperidone on responses to cocaine in cocaine addicts
38. Extracellular dopamine, norepinephrine, and serotonin in the ventral tegmental area and nucleus-accumbens of freely moving rats during intracerebral dialysis following systemic administration of cocaine and other uptake blockers
39. Cocaine receptors on dopamine transporters are related to self-administration of cocaine
40. Cocaine self-administration in dopamine-transporter knockout mice
41. A review of the effects of dopamimetic agents in humans: Implications for medication development
42. A review of the effects of dopaminergic agents on humans, animals and drug seeking behavior, and its implications for medication development: Focus on GBR12909
43. Identification of a GBR12935 homolog, LR1111, which is over 4000-fold selective for the dopamine transporter, relative to serotonin and norepinephrine transporters
44. 125I]RTI-55
45. Phentermine and fenfluramine: Preclinical studies in animal models of cocaine addiction
46. 125I]RTI-55 in membranes prepared from human, monkey and guinea pig caudate
47. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates: Implications for primary pulmonary hypertension
48. Neurochemical neutralization of methamphetamine with high affinity nonselective inhibitors of biogenic amine transporters: A pharmacological strategy for treating stimulant abuse
49. From synapse to vesicle: The reuptake and storage of biogenic amine neurotransmitters
50. Self-injection in baboons of amphetamines and related designer drugs
51. An escalating dose 'binge' model of amphetamine psychosis: Behavioral and neurochemical characteristics
52. Cocaine reward models: Conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice
53. Differential effects of the enantiomers R(-) and S(+) oxaprotiline on major endogenous depression, the sleep EEG and neuroendocrine secretion: Studies on depressed patients and normal controls
54. 11C]WIN35,428 PET scans
55. Psychological and cardiovascular effects and short-term sequelae of MDMA ('ecstasy') in MDMA-naive healthy volunteers
56. Neurobiology of addiction
57. Evaluation of the abuse liability of aminorex
58. Regulation of extracellular dopamine by the norepinephrine transporter